Clinical Effectiveness and Safety of Vedolizumab Intravenous in Real World Clinical Practice in Ulcerative Colitis Korean Patients: a Multicenter Post-marketing Observational Study
Phase of Trial: Phase IV
Latest Information Update: 26 Feb 2019
Price : $35 *
At a glance
- Drugs Vedolizumab (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Takeda
- 20 Feb 2019 Status changed from recruiting to completed.
- 05 Oct 2018 Planned End Date changed from 31 Oct 2018 to 30 Jan 2019.
- 05 Oct 2018 Planned primary completion date changed from 31 Oct 2018 to 30 Jan 2019.